Skip to main content

Table 2 Dynamics of sTILs from baseline to 3 weeks by arm (n = 282)

From: Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial

Dynamics

3wTIL− 

n (%)

3wTIL+

n (%)

3wLC

n (%)

NP/G

TIL−

70 (53.4%)

36 (27.5%)

25 (19.1%)

TIL+

7 (25.0%)

19 (67.9%)

2 (7.1%)

NP/C

TIL−

69 (69.7%)

10 (10.1%)

20 (20.2%)

TIL+

3 (12.5%)

12 (50.0%)

9 (37.5%)

All patients

TIL−

139 (60.4%)

46 (20.0%)

45 (19.6%)

TIL+

10 (19.2%)

31 (59.6%)

11 (21.2%)